![Loading Events](https://lifescievents.com/wp-content/plugins/the-events-calendar/src/resources/images/tribe-loading.gif)
Arrowhead Pharmaceuticals Presentation of Topline Data from Fazirsiran Phase 2 SEQUOIA Study
![Banners-13 Banners-13](https://lifescievents.com/wp-content/uploads/2022/12/Banners-13.png)
DATE: | January 9, 2023 |
---|---|
TIME: | 8:30 AM EST |
LOCATION: | Virtual |
About The Event
Join us for a virtual webcast with Arrowhead Pharmaceuticals to present topline data from the SEQUOIA Phase 2 study of fazirsiran and discuss the design for the planned Phase 3 study. Fazirsiran is a potential first-in-class investigational RNA interference (RNAi) therapy designed to reduce production of the mutant alpha-1 antitrypsin protein (Z-AAT) as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Fazirsiran is being developed under a collaboration and licensing agreement between Arrowhead and Takeda (TSE: 4502 / NYSE: TAK).